Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTBRUGA)

DTT Name	CDK inhibitor 4C p18-INK4c (CDKN2C)
Synonyms	P18-INK6; P18-INK4c; P18(INK4c) protein; P18(INK4c); P18 INK4c protein; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 4 inhibitor C
Gene Name	CDKN2C
DTT Type	Literature-reported target	[1]
UniProt ID	CDN2C_HUMAN
TTD ID	T45755
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MAEPWGNELASAAARGDLEQLTSLLQNNVNVNAQNGFGRTALQVMKLGNPEIARRLLLRG ANPDLKDRTGFAVIHDAARAGFLDTLQTLLEFQADVNIEDNEGNLPLHLAAKEGHLRVVE FLVKHTASNVGHRNHKGDTACDLARLYGRNEVVSLMQANGAGGATNLQ
Function	Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB. Interacts strongly with CDK6, weakly with CDK4.
KEGG Pathway	Endocrine resistance (hsa01522 ) Cell cycle (hsa04110 ) Cushing syndrome (hsa04934 ) Human T-cell leukemia virus 1 infection (hsa05166 ) Transcriptional misregulation in cancer (hsa05202 )
Reactome Pathway	Senescence-Associated Secretory Phenotype (SASP) (R-HSA-2559582 ) Oncogene Induced Senescence (R-HSA-2559585 ) Cyclin D associated events in G1 (R-HSA-69231 ) Oxidative Stress Induced Senescence (R-HSA-2559580 )

References

1	An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J Immunol. 2001 Sep 15;167(6):3285-92.